|
Synonyms: INCSHR1210 | SHR-1210
camrelizumab is an approved drug (China (2019))
Compound class:
Antibody
Comment: Camrelizumab is a fully human anti-programmed cell death 1 (PD-1) monoclonal antibody being developed as an immuno-oncology therapeutic.
SARS-CoV-2 and COVID-19: Clinical efficacy of camrelizumab plus thymosin in patients with COVID-19 will be evaluated in clinical trial NCT04268537. |
Classification  |
|
| Compound class | Antibody |
| Approved drug? | Yes (China (2019)) |
| International Nonproprietary Names |
|
| INN number | INN |
| 10400 | camrelizumab |
| Synonyms |
| INCSHR1210 | SHR-1210 |
| Database Links |
|
| Specialist databases | |
| IMGT/mAb-DB | 659 |
Reactome Drug
|
R-ALL-9679471 |
|
Reactome Reaction
|
R-HSA-9679421 |
| Other databases | |
| GtoPdb PubChem SID | 354702231 |
| Search PubMed clinical trials | camrelizumab |
| Search PubMed titles | camrelizumab |
| Search PubMed titles/abstracts | camrelizumab |
